Skip to content

EVA: Evaluation of EVOKE Therapy Metrics Generated Using the Evoke System With EVA

EVA: Evaluation of EVOKE Therapy Metrics Generated Using the Evoke System With EVA

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07267715
Enrollment
40
Registered
2025-12-05
Start date
2025-11-30
Completion date
2026-11-01
Last updated
2025-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pain

Keywords

Treatment of chronic pain of the trunk and/or limbs.

Brief summary

The Evoke Spinal Cord Stimulator (SCS) System (Evoke® System) is an FDA-approved device that is used to manage long lasting, severe pain that is not relieved by typical medical treatments. This research registry is being conducted to collect data from patients treated with a SCS device in order to determine how the device impacts their chronic pain condition. Specifically, the study aims to: * Evaluate data collected from the SCS system on how well the system is working. * Evaluate the feasibility of programming the SCS system independently without external assistance. * Evaluate changes in physical function, fatigue, pain interference, mood, sleep, daily activities, pain control, and overall satisfaction with the device.

Interventions

Spinal cord stimulation system as an aid in the management of chronic intractable pain of the trunk and/or limbs; and will be used within its commercially approved indication.

Sponsors

Saluda Medical Pty Ltd
CollaboratorINDUSTRY
Dustin Reynolds, MD
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subject is not pregnant and 18 years of age or older at the time of enrollment. * Subject has a minimum NRS score of 6 or higher (where 10 indicates the worst imaginable pain) in primary area of pain at baseline. * Subject is planning to have a temporary trial with the Evoke® System to aid in the management of chronic intractable pain of the trunk and/or limbs. * Subject is willing to program the Evoke® System using EVA™ under the supervision of the study investigator or Qualified Health Professional. * Subject is being trialed with a neurostimulation system for the first time. * Subject is able to read and understand English. * Subject is capable of subjective evaluation; subject must be able to describe and rate his/her pain levels. * Subject is willing and capable of giving informed consent. * Subject is willing and able to comply with study-related requirements, procedures, and visits. * Subject has adequate cognitive ability to use a patient programmer and recharger as determined by the Investigator.

Exclusion criteria

\- There are no

Design outcomes

Primary

MeasureTime frameDescription
Evoke® therapy neural panel metrics generated by EVA™At time of EVA programming and through study completion (up to 30 days)The core neural panel metric generated by the Saluda Medical Evoke® therapy system, specifically via its EVA™ sensing technology, is the Evoked Compound Action Potential (ECAP). ECAPs are objective neurophysiological biomarkers that represent the spinal cord's electrical response to stimulation.

Secondary

MeasureTime frameDescription
Pain Locus of ControlUp to 30 daysThe PLOC classifies the location in which individuals realize predominantly who or what stops the control of their pain. Factor analysis of the main components of this new scale revealed four dimensions: internal LC, chance LC, other people LC (friends and family), doctor and health professional LC. PLOC will be measured using an adapted version of a general purpose, condition-specific Multidimensional Health Locus of Control (MHLC) scale. The responses will be shortened from 6-level to 4-level: strongly agree, agree, disagree and strongly disagree. Each subscale receives an independent score, ranging from 6 to 24 (internal and chance LC subscales) and from 3 to 12 (health professionals and others LC subscales).
Numeric Rating ScaleUp to 30 daysThe NRS is a subjective measure of pain. It is a commonly used pain assessment tool where individuals rate their pain on a scale of 0 to 10, with 0 representing no pain and 10 representing the worst possible pain. It's a simple, quick, and widely accepted method for quantifying pain intensity.
PROMIS-29+2Up to 30 daysThe PROMIS-29+2 consists of the PROMIS-29 profile (v2.1) and two PROMIS Cognitive Function Abilities items. The PROMIS-29 is a 29-item profile instrument that assesses 8 universal domains (not disease-specific): Physical Function, Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles and Activities, Pain Interference, and Pain Intensity.

Countries

United States

Contacts

Primary ContactMelissa B. Showe
melissa.showe@mchs.com1-614-775-6607

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026